Purple Biotech Valuation
| PPBT Stock | USD 2.60 0.07 2.77% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Purple Biotech holds a recent Real Value of $10.44 per share. The prevailing price of the company is $2.6. Our model determines the value of Purple Biotech from analyzing the company fundamentals such as Shares Outstanding of 2.65 M, return on equity of -0.12, and Shares Owned By Institutions of 1.78 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Purple Biotech's price fluctuation is somewhat reliable at this time. Calculation of the real value of Purple Biotech is based on 3 months time horizon. Increasing Purple Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Purple Biotech's intrinsic value may or may not be the same as its current market price of 2.60, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.6 | Real 10.44 | Hype 2.78 | Naive 2.85 |
The intrinsic value of Purple Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Purple Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Purple Biotech helps investors to forecast how Purple stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Purple Biotech more accurately as focusing exclusively on Purple Biotech's fundamentals will not take into account other important factors: Purple Biotech Total Value Analysis
Purple Biotech is at this time forecasted to have valuation of (480.54 K) with market capitalization of 6.89 M, debt of 183 K, and cash on hands of 36.02 M. The negative valuation of Purple Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Purple Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(480.54 K) | 6.89 M | 183 K | 36.02 M |
Purple Biotech Asset Utilization
One of the ways to look at asset utilization of Purple is to check how much profit was generated for every dollar of assets it reports. Purple Biotech holds a negative application of assets of -0.13 pct., losing $0.001283 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Purple Biotech shows how discouraging it operates for each dollar spent on its assets.Purple Biotech Ownership Allocation
Roughly 96.37 pct. of Purple Biotech outstanding shares are held by general public with 1.85 % owned by insiders and only 1.78 (%) by third-party entities.Purple Biotech Profitability Analysis
Net Loss for the year was (7.28 M) with loss before overhead, payroll, taxes, and interest of (62 K).About Purple Biotech Valuation
The stock valuation mechanism determines Purple Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Purple Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Purple Biotech. We calculate exposure to Purple Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Purple Biotech's related companies.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Purple Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Purple Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.6 M |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.